Open AccessCharacteristics of meibomian gland dysfunction in patients with Stevens–Johnson syndrome
Author(s) -
Tina Shrestha,
Hyun Sik Moon,
Won Suk Choi,
Hyeon Jeong Yoon,
Yong Sok Ji,
Mayumi Ueta,
Kyung Chul Yoon
Publication year - 2019
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000016155
Subject(s) - medicine , meibomian gland , risk factor , gastroenterology , ophthalmology , eyelid
To evaluate the characteristics of meibomian gland dysfunction (MGD) in patients with Stevens–Johnson Syndrome (SJS) and investigate the risk factors for severe MGD. Sixteen patients with a history of SJS were evaluated for MGD. To assess the SJS severity acute ocular involvement score (AOS), acute systemic involvement score (ASS), and chronic ocular manifestation score (COMS) were measured. Meibomian gland parameters were evaluated using meibomian gland dropout score (meiboscore - using a Keratograph 5 M), meibum expression score (MES), meibum quality score (MQS), and lid margin abnormality score (LMAS). Correlations between severity of meibomian gland parameters and degree of ocular and systemic involvement of SJS were analyzed. Risk factors for development of severe MGD were identified. The patients’ mean age was 32.0 ± 14.3 years. Four patients were men and 12 were women. MGD had developed in 14 patients (87.5%). The meibomian gland parameters were significantly correlated with ocular and systemic degree of SJS as evaluated using AOS ( P < .01), ASS ( P < .01), and COMS ( P < .01). Patients with severe MGD had a higher AOS ( P < .01) and COMS ( P = .02) values than those without severe MGD. On multivariate analysis, AOS higher than 2 was a significant risk factor for developing severe MGD ( P = .03). MGD was a common ocular manifestation with SJS patients. Severity of meibomian gland parameters was correlated with AOS, ASS, and COMS, and the presence of acute ocular complications was a risk factor for severe MGD in patients with SJS.